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Abstract
Glioblastoma multiforme (GBM) is the most common and severe form of brain cancer. The median survival
time of patients is approximately 12months due to poor responses to surgery and chemoradiation. To understand
the mechanisms involved in radioresistance, we conducted a genetic screen using an shRNA library to identify
genes in which inhibition would sensitize cells to radiation. The results were cross-referenced with the Oncomine
and Rembrandt databases to focus on genes that are highly expressed in GBM tumors and associated with poor
patient outcomes. Spermidine/spermine-N1-acetyltransferase 1 (SAT1), an enzyme involved in polyamine
catabolism, was identiﬁed as a gene that promotes resistance to ionizing radiation (IR), is overexpressed in
brain tumors, and correlates with poor outcomes. Knockdown of SAT1 using shRNA and siRNA approaches in
multiple cell and neurosphere lines resulted in sensitization of GBM cells to radiation in colony formation assays
and tumors, and decreased tumorigenesis in vivo. Radiosensitization occurred speciﬁcally in G2–Mand S phases,
suggesting a role for SAT1 in homologous recombination (HR) that was conﬁrmed in a DR-GFP reporter system.
Mechanistically, we found that SAT1 promotes acetylation of histone H3, suggesting a new role of SAT1 in
chromatin remodeling and regulation of gene expression. In particular, SAT1 depletion led to a dramatic
reduction in BRCA1 expression, explaining decreased HR capacity. Our ﬁndings suggest that the biologic
signiﬁcance of elevated SAT1 expression in GBM lies in its contribution to cell radioresistance and that SAT1may
potentially be a therapeutic target to sensitizeGBMto cancer therapies. Cancer Res; 74(23); 6925–34.2014AACR.
Introduction
Glioblastoma multiforme (GBM) is the most common and
aggressive of the gliomas, a group of tumors that derive from
glia or their precursors in the central nervous system (CNS).
Patients with GBM have a median survival time of approxi-
mately 12 months, and only 3% to 5% of the patients survive
more than 3 years (1). GBM is characterizedby a heterogeneous
population of cells that are genetically unstable and inﬁltrative,
and comprise some of themost challenging therapeutic targets
due to their anatomic location, the blood barrier, and poor
responses to conventional therapies (2). Although the standard
of care for newly diagnosed patients includes resection, fol-
lowed by concurrent radiotherapy and temozolomide (3), the
response to radiation and DNA-damaging agents remains
insufﬁcient as tumors display resistance and a propensity to
recur. Although several mechanisms have been proposed to
explain the radioresistance in GBM (4–6), the molecular bases
of radioresistance remain incompletely deﬁned.
To identify novel mediators of radiation resistance in glio-
blastoma,weperformeda genetic screenusing an shRNA library
on two GBM cell lines. The results showed a list of overlapping
geneswith a variety of disparate functions. Analyses of the genes
using public databases revealed spermidine/spermine-N1-acet-
yltranferase (SAT1) as a novel regulator of radiation response
with no previously described associationwithDNA repair. SAT1
catalyzes the acetylation of polyamines spermidine and sper-
mine to form acetyl derivatives and is considered a rate-limiting
enzyme in polyamine catabolism, leading to degradation or
excretion (7). Paradoxically, polyamines, ubiquitous cationic
molecules, are known radioprotectors through their capacity
to compact DNA (8–10), confounding speculation of how SAT1
could promote resistance to radiation.
Histone acetylation has been shown to have an essential role
in DNA repair allowing critical proteins to be loaded at sites of
damage (11), as well as altering gene expression by decom-
pacting chromatin (12). Indeed, cellswithDNAbreaksmaintain
high levels of acetylation (13). In a parallel role to histone
acetylation, we hypothesized that polyamine acetylation by
SAT1 may have an integral role in double-strand break (DSB)
repair through alteration of chromatin, and thereby contribute
to radiation resistance.Our results indicate that SAT1 increases
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acetylation of histone H3, increasing BRCA1 expression, and
allowing activation of the homologous recombination (HR)
pathway to repair DNA damage. The ﬁndings support a novel
role for SAT1 in histone acetylation and DNA repair, and
suggest that the biologic signiﬁcance of SAT1 expression in
GBM lies in its contribution to radio- and chemoresistance.
SAT1 may represent a therapeutic target to sensitize GBM to
cancer therapies.
Materials and Methods
Cell lines and reagents
U87MG and LN229 cells were obtained from the ATCC.
D54MG and D317MG lines were gifts of Dr. Jeremy Rich
(Cleveland Clinic Foundation, Cleveland, OH); MCF7 DR-GFP
cells were from Dr. Junran Zhang (Case Western Reserve
University, Cleveland, OH). Neurosphere cell lines GBM 0821
and 0913 were a gift of Dr. Angelo Vescovi (University of
Bicocca, Milan; to E.E. Bar). The lines were not independently
authenticated. All lines were used in early passage. D-luciferin
came from Byosynth International. Trichostatin A (TSA) was
used at 250 ng/mL (Sigma-Aldrich). Antibodies: BRCA1 (sc-
6954; Santa Cruz Biotechnology), Mre11 (cs4847; Cell Signaling
Technology), NBS1 (cs3002), Rad51 (sc-8349), Histone H3 (sc-
8654), acetyl-H3 (06-599; Upstate-Millipore), SAT1 (sc-67159).
Quantitative real-time PCR (qRT-PCR) was performed using
2XSYBR-Green Master mix (Roche) and normalized to b-actin.
Primer sequences: SAT1 F-50GCTGATCAAGGAGCTGGCTA-
30, R-50CAACAATGCTGTGTCCTTCC-30; BRCA1 F-50TGGAAG-
AAACCACCAAGGTC-30, R-50ACCACAGAAGCACCACACAG-
30; Actin F-50CATGTACGTTGCTATCCAGGC-30, R-50CTCCTT-
AATGTCACGCACGAT30; ODC F-50ACATCCCAAAGCAAAG-
TTGG-30, R-50AGCTGACACCAACAACATCG 30.
shRNA screen/knockdown
The Decode RNAi Screening Library was performed as
directed (Open Biosystems). Microarray hybridizations were
performed by the StanfordMicroarray Facility. For siRNA, cells
were transfected with DharmaFECT#1 and either 25 nmol/L
control oligos or siSAT1 (Dharmacon). Stable SAT1 knock-
down was performed with lentiviral shRNA pLKO.1 clones:
TRCN0000035250 and TRCN0000035252 (Thermo Fisher Sci-
entiﬁc), shRNA GFP was used as control. Cells were selected
with puromycin at 1 mg/mL.
Colony formation assay
Radiation was performed with a 137Cs irradiator (Shep-
herd). A total of 500 to 10,000 cells per plates were stained
after 10 days with 0.1% crystal violet. Assays were done 3
times with individual samples in triplicate. Cell sorting
was performed on live D54MG cells stained with Hoechst
33342 on an iCyt Reﬂection. Cells were then irradiated and
plated. Clonogenic assays of neurosphere lines were per-
formed in plates coated with 200 mL of 2 mg/mL poly (2-
hydroxyethyl methacrylate; Sigma) in 95% ethanol. Wells
were overlaid with 2 mL of neuro stem cell (NSM) 1.5%
methyl-cellulose media. A total of 104 cells in NSM were
mixed 1:4 with methyl cellulose, and fed every 3 days.
Sphere formation was monitored and scored by light
microscopy after 12 days with Metamorph software, using
a size cutoff of 100 mm.
Immunoﬂuorescence
Cells were ﬁxed in 3% formaldehyde and stained using
standard procedures: BRCA1 antibody (sc-6954), secondary
Alexa-Fluor 594 anti-mouse (A11032; Invitrogen). Slides were
mounted in Vectashield with DAPI (Vector Laboratories).
Immunoﬂuorescence was observed at100, foci were counted
from at least 50 cells.
Tumor formation assay
Eight-week-old athymic BALB/c mice were injected inta-
cranially with 105 luciferase-expressing SAT1 or GFP knock-
down GBM0821, GBM0913 neurosphere cells. Tumor growth
was monitored twice weekly and quantiﬁed using biolumi-
nescent imaging. Signal intensity was measured as photon
counts within a region of interest. Animal appearance,
behavior, and weight were monitored to evaluate tumor
progression. Subcutaneous U87MG tumors were produced
by injection of 5 106 cells in nude mice, and measured with
calipers twice weekly. When tumors reached between 100
and 200 mm3, animals were randomized and injected intra-
tumorally with 500 pmol/L of siRNA packaged in ECO
(1-aminoethyl)iminobis[N-(oleicylcysteinyl-1-ami no-ethyl)-
propionamide] as described previously (14). After 48 hours,
half of the tumors were irradiated.
Chromatin immunoprecipitation
Chromatin immunoprecipitation (ChIP) was performed as
described previously (15). The primers used were: BRCA1 F-
50GGCAGGCATTTATGGCAAAC-30, R-50TTCGGAAATCCAC-
TCTCCCACG-30. b-Actin F-50CCGAAAGTTGCCTTTTATGG-
30, R-50CAAAGGCGAGGCTCTGTG-30. Acetylated H3 antibody
(Upstate-Millipore 06-599). Samples were normalized to input.
Polyamine levels
Polyamines were quantiﬁed using mass spectrometry.
Proteins were precipitated with heptaﬂuorobutyric acid, and
supernatants containing polyamines were ﬁltered through
an ion-exchange membrane for salt removal. An internal
standard, diethylspermine, was added into the samples that
were injected into an Agilent 6420 triple quadrupole LC/MS
system for analysis along with a 7-point standard curve. The
chromatographic separations were achieved using a guarded
Luna reversed phase CN column (3  150 mm; Phenom-
enex). Concentrations were calculated from the standard
curves. Three biologic replicates were assayed for each
sample.
HR assays/comet assays
Cells were transfected with 2 mg of pcDNA or I-Sce
plasmids using lipofectamine 2000 (Invitrogen), incubated
48 hours, and analyzed by ﬂow cytometry as described
previously (16). Comet assays were performed as directed
(Trevingen), and quantiﬁed with ComeScore software. At
least 41 cells per sample were measured, and done in
duplicate.
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Statistical Analyses
Student t tests were used throughout the study to test the
signiﬁcance of differences between samples. Survival analyses
were performed by log-rank tests in GraphPad Prism.
Results
shRNA screen identiﬁes SAT1 as a mediator of
radioresistance
To identify novel mediators of radiation resistance in GBM,
we performed a genetic screen using a lentiviral-mediated
shRNA library on two GBM lines. U87MG and LN229 were
chosen based on known different genetic characteristics to
maximize the application of hits. U87MG is p53 wild-type and
PTEN-null; LN229 is p53 mutant and PTEN wild-type (17, 18).
Thus, many classic DNA damage pathway genes will be
excluded because of the differential status of p53. The library
was comprised of roughly 30,000 barcoded shRNAs, which
target more than 10,000 genes. GBM cells were infected with
pools of lentiviruses at an estimatedmultiplicity of infection of
0.3 to ensure that cells were infected with only once. Following
selection, cells were divided into treatment (2 Gy of IR) and
control groups, maintained for 72 hours after irradiation, and
lysed for genomic DNA. The screens were performed in
duplicate.
Ostensibly, shRNA knockdown of genes that confer radio-
protection should result in the sensitization of cells to radi-
ation and depletion from the population. Knockdown of genes
that promote sensitivity to radiation should result in protec-
tion and increased survival. Identiﬁcation of shRNAs that
altered the sensitivity of cells to radiation was performed by
determining the relative abundances of the shRNA barcodes in
the genomic DNA of the treatment group versus the control
group. Barcodes were ampliﬁed by PCR, labeled with Cy3 or
Cy5, and hybridized onto barcodemicroarrays. The raw data of
the U87MG screen are represented in Fig. 1A: Log2-trans-
formed ratios of barcode abundances in the irradiated sample
divided by the control. Of 21,555 detected barcodes, 1,868 were
decreased by 1.5-fold or more; 764 were decreased by 2-fold or
more; and 126 were decreased by 4-fold ormore (Fig. 1B). As an
internal positive control for the screen, 47 shRNAs targeting
genes known to be involved in DNA repair were found (e.g.,
ATM, PARP1, RAD9, and RAD51). When the results of the
U87MG and LN229 screens were combined into one dataset, 79
shRNAs that were decreased 1.5-fold or more were identiﬁed,
10 were decreased 2-fold or more, and none were decreased by
4-fold. Geneswith functions as broad ranging as synaptic nerve
transmission to cell motility were included in the 10 genes
(Supplementary Table S1; Microarray data are available in the
ArrayExpress database, accession number E-MTAB-2861).
Because of its metabolic role as a regulator of DNA compac-
tion, we further investigated SAT1.
SAT1 is overexpressed in GBM and correlates with
poorer outcome
As a primary ﬁlter for relevance to GBM, expression levels
of hits were queried in Oncomine. SAT1 expression was
found elevated in a variety of brain and CNS cancers, derived
from data from ﬁve studies of glioblastoma, two oligoden-
droglioma, one malignant glioma, one astrocytoma, and one
Figure 1. Relevance of SAT1 to GBM. A, raw data of the U87MG shRNA screen; abundance of individual barcodes represented as log2-transformed ratios of
irradiated over nonirradiated cells, shadedby level of depletion. B, quantiﬁcation of barcode abundance ratios. A total of 1,868 barcodes decreased1.5-fold;
764 decreased 2-fold; and 126 decreased 4-fold. C, Oncomine data of SAT1 expression in brain tumors (N, normal; T, tumor). D, Rembrandt survival
curves of patients with glioma with high SAT1–versus low SAT1–expressing tumors.
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oligoastrocytoma. The expression levels of SAT1 in cancers
versus normal tissues in four of the studies are displayed
in Fig. 1C. In the Shai, Bredel, and The Cancer Genome Atlas
(TCGA) studies of GBM samples, SAT1 was overexpressed by
factors of 3.11 (P < 0.0001), 3.33 (P ¼ 0.0009), and 2.28 (P <
0.0001), respectively; in the Pomeroy study of malignant
gliomas, SAT1 was overexpressed by 3.33 (P ¼ 0.0042). We
next looked at SAT1 Rembrandt, an NCI/NINDS database of
gene expression and survival data from >340 brain tumor
cases. Using SAT1 expression to categorize the samples, we
observed that a 2-fold increase in SAT1 expression corre-
lated with a signiﬁcant decrease in survival time (603 vs. 450
days, P ¼ 0.0008, log-rank test; Fig. 1D). Levels of SAT1 could
not identify patients with poorer or better outcomes among
patients with GBM, but could delineate patients with glioma
with the poorest prognoses (i.e., patients with GBM) from
the rest. Together, these data suggest SAT1 may play a role in
GBM tumors and their radioresistant phenotype.
SAT1 knockdown sensitizes GBM cells to radiation
To verify SAT1 knockdown can sensitize cells to radiation,
two unique lentiviral shRNAs were stably expressed ﬁrst in
U87MG cells, and clonogenic survival assays were performed
with different doses of ionizing radiation (IR). qRT-PCR and
Western blot analysis were used to verify knockdown (Fig. 2
insets; and Supplementary Fig. S1). Importantly, the levels of
knockdown consistently achieved were in the range of the
levels found elevated in tumor samples, that is, 3- to 5-fold.
Both shRNAs sensitized U87MG cells, conﬁrming the results of
the screen (Fig. 2A). We observed that the depletion of SAT1
Figure 2. SAT1 knockdown
sensitizes GBM cells to radiation.
A, clonogenic survival of U87MG
cells with two SAT1 shRNAs. B
and C, clonogenic survival of
D317MG and D54MG with stable
SAT1 knockdown. D, clonogenic
survival of D54 with transient
SAT1 knockdown. E and F,
clonogenic survival of primary
GBM neurosphere lines GBM0821
and GBM0913 with stable SAT1
knockdown; error bars, SDs;
, P  0.001 (A); P  0.002 (B);
P  0.013 (C); P  0.005 (D);
P  0.019 (E); and P  0.036 (F).
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also sensitized D317MG and D54MG cell lines to IR, with dose-
modifying factors at 10% survival of 1.14, 1.32, and 1.36 for
U87MG, D317MG, and D54MG, respectively (Fig. 2B and C). To
determine whether transient knockdownwas also sufﬁcient to
sensitize cells to radiation, we performed siRNA in the D54MG
line and found similar sensitization (Fig. 2D).
Tumors are comprised of cells with differing potentials to
initiate or repopulate. The importance of such "tumor-initiat-
ing cells" in cancer therapy has become of peak interest due to
their tendencies to be particularly resistant (5). We next
evaluated the effect of SAT1 knockdown on radiation response
of primary GBM neurosphere cell lines (GBM0821 and
GBM0913) that are enriched in tumor-initiating cells (19) in
a 3D neurosphere colony assay. We again observed sensitiza-
tion to radiation following SAT1 depletion; GBM0821 by a
factor of 1.70, and GBM0913 by a factor of 1.35 (Fig. 2E and F).
Together, the results show that inhibition of SAT1 is sufﬁcient
to sensitize multiple tumor cell lines to radiation.
SAT1 promotes GBM tumor growth and decreases
survival in nude mice
Clonogenic capacity in vitro is often used as a surrogate for
tumorigenic potential in vivo. Besides observing increased
radiosensitivity in SAT1-depleted neurospheres, we also found
decreased in clonogenic capacity absent of radiation. To
determine whether SAT1 affects tumor growth, nude mice
were injected intracranially with luciferase-expressing SAT1
knockdown GBM0821 and GBM0913 neurospheres and com-
pared with shGFP knockdown cells. Tumor growth was mon-
itored using bioluminescent imaging. Over a 80- to 90-day
period, we found that mice injected with control cells devel-
oped tumors more rapidly than mice injected with SAT1
knockdown cells from both neurosphere lines (Fig. 3A and
B). Kaplan–Meier curves demonstrated signiﬁcantly increased
survival of animals with shSAT1 tumors compared with con-
trols (Fig. 3C and D). In the GBM0913 line, control animals
survived an average of 65.5 days after injection, whereas the
shSAT1 animals survived 83.0 days (P ¼ 0.0047). In the
GBM0821 line, control animals survived an average of 47.0
days, and the shSAT1 animals survived 77.0 days (P ¼ 0.0064).
To determine whether eventual tumor growth in the shSAT1
neurosphere lines correlatedwith regained expression of SAT1,
tumors were excised and subjected to qRT-PCR for SAT1. We
found, however, that SAT1 knockdown was maintained in
tumor samples over the course of the experiment, suggesting
that SAT1 deﬁciency limited the growth of the tumor, rather
than inducing a selective pressure against SAT1 knockdown
(Supplementary Fig. S2A and S2B). Thus, elevated SAT1 expres-
sion in GBM promotes tumorigenesis in addition to reducing
radiosensitivity.
To test whether SAT1 depletion can sensitize tumors in vivo,
transient knockdown in U87MG tumors was achieved by
intratumoral injection of siRNA using cationic lipid-based
nanoparticles (14). Subcutaneous U87MG tumors 100 to 200
mm3 were injected with 500 pmol/L of siSAT1 or RISC control
packaged in 1-aminoethyl)iminobis[N-(oleicylcysteinyl-1-ami-
no-ethyl)-propionamide] (ECO), and subsequently irradiated
48 hours later with 8 Gy. Tumors were measured twice weekly,
until the tumors reached 1.5 cm3. As can be seen in Fig. 3E,
whereas transient knockdown of SAT1 had no effect on tumor
growth, and 8 Gy IR had a modest effect on tumor growth, the
combination of siSAT and radiation led to the most signiﬁcant
delay on tumor growth. Likewise, Kaplan–Meier survival
curves of the animals demonstrated a signiﬁcant beneﬁt to
siSAT1 and radiation over radiation alone (Fig. 3F). Together,
the data argue that the sensitization of GBM cells in vitro exists
in vivo as well.
Global polyamine catabolism is not the mechanism of
SAT1-mediated radioprotection
Polyamine-induced DNA compaction/aggregation is known
to be a means of radioprotection (8, 10, 20). Thus, how SAT1, a
rate-limiting enzyme of polyamine catabolism, would protect
GBM cells from radiation is nonintuitive. To gain insight into
the mechanism of SAT1-mediated radioprotection, we deter-
mined by mass spectrometry the levels of polyamines in
Figure 3. SAT1 knockdown inhibits
GBM tumor growth and increases
survival in nude mice. A and B,
bioluminescence of orthotopic
tumor growth of SAT1 knockdown
GBM0821 and GBM0913
neurospheres. C and D, Kaplan–
Meier survival curves of GBM0821
and GBM0913 cells with SAT1 or
GFP knockdown. GBM0913
controls (n¼4) survivedanaverage
of 65.5 days after injection; shSAT1
(n ¼ 5) survived 82.0 days (P ¼
0.0047). GBM0812 controls (n ¼ 5)
survived an average of 47.0 days;
shSAT1 (n ¼ 5) survived 77.0 days
(P ¼ 0.0064). E, U87MG tumor
response curves following
intratumoral siRNA and radiation.
F, Kaplan–Meier survival curves of
mice in E.
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control and SAT1 knockdown cells. Surprisingly, stable knock-
down of SAT1 did not result in increases in steady-state levels
of spermine or spermidine (Fig. 4A). One explanation for this
observation might be that stable knockdown cells acclimate to
decreased SAT1 gene expression, as enzymes in the polyamine
pathway are known to be tightly regulated by feedback
mechanisms (21). To determine whether decreased catabolic
enzyme expression (i.e., SAT1) was accompanied by decreased
anabolic enzyme levels, we measured the expression of the
rate-limiting regulator of polyamine synthesis, ornithine decar-
boxylase 1 (ODC1; ref. 21). We found that ODC1 expression
mirrored SAT1, displaying signiﬁcant repression with both
SAT1 shRNAs (Fig. 4B). Thus, global alterations in polyamine
levels are not evident in stable SAT1 knockdown cells, and
therefore do not correlate with radiosensization following
SAT1 depletion.
SAT1 protects GBM cells from irradiation by promoting
HR
We next tested whether alterations in the cell cycle could
explain increased sensitivity to radiation by increasing the
fraction of cells in radiosensitive phases (e.g., G1). We assessed
the cell-cycle distribution of D54MG cells following stable
knockdown of SAT1, but found no signiﬁcant differences (Fig.
5A). In addition, SAT1 expression levels were not cell-cycle
dependent (Fig. 5B). In contrast, when we assessed the sensi-
tivity of cells sorted by ﬂow cytometry using Hoechst 33342
(Supplementary Fig. S3), we found that S phase and G2–M
phase cells were uniquely sensitized to radiation following
knockdown, whereas G1 phase cells were unaffected (Fig. 5C).
S phase cells displayed a dose-modifying factor of 1.90, at 10%
survival; G2–M cells displayed a factor of 1.86.
HR is the predominant DSB repair pathway in G2–M and S
phases of the cycle due to the presence of homologous sister
chromatids after replication (22). Our ﬁndings of radiosen-
sitization in G2–M and S phases led us to investigate the
effect of SAT1 on HR using an established MCF7-based HR
reporter assay (DR-GFP; ref. 23). SAT1-deﬁcient cells dem-
onstrated a 54% decrease in HR compared with shGFP cells
(P ¼ 0.012; Fig. 5D). To test whether SAT1 knockdown would
sensitize cells to an S phase–speciﬁc DNA-damaging agent,
we treated D54MG cells with physiologically relevant con-
centrations of the topoisomerase I inhibitor Camptothecin
(CPT). Chronic 10 nmol/L CPT exposure reduced colony
survival in control cells by 10-fold; in contrast, CPT exposure
led to a 1,000-fold reduction in SAT1 knockdown colony
survival (Fig. 5E). Thus, SAT1 depletion sensitizes cells to IR
and S phase agents by inhibiting HR.
SAT1 depletion decreases BRCA1 foci and expression
levels
To gain insight into the mechanism of regulation of HR by
SAT1, we measured DNA damage after IR by comet assay in
shGFP and shSAT1 D54MG cells. We found basal levels of
damage and induced levels of damage after 10 Gy were similar.
After 6 hours, however, SAT1-depleted cells demonstrated a
marked decrease in the ability to repair compared with control
(Fig. 6A). The HR protein BRCA1 was then used to identify HR
foci in U87MG and D54MG SAT1 knockdown and control cells
at 0 or 6 hours following exposure to IR (Fig. 6B). Although
control cells displayed a potent induction of BRCA1 foci, SAT1
knockdown cells from both the U87MG and D54MG lines
exhibited diminished capacity to produce foci. Both the num-
ber of cells with foci (64% vs. 16% for U87MG shGFP vs. shSAT1;
and 66% vs. 32% for D54 shGFP vs. shSAT1), and the number of
foci per cell were reduced (Fig. 6C). As the proportion of cells in
S andG2–Mphaseswere unchanged between control and SAT1
knockdowns, the data suggest that SAT1-deﬁcient cells have
reduced HR signaling.
We next askedwhether HR pathway components are altered
in SAT1 knockdown cells. Western blotting revealed that
BRCA1 itself is severely diminished in SAT1-depleted cells
(Fig. 6D). In contrast, expression levels of MRE11, NBS1, and
Rad51 remained unchanged. As BRCA1 could be regulated at
various points, we examined mRNA and found consistent
reductions of expression of BRCA1 after SAT1 depletion,
suggesting regulation of BRCA1 by SAT1 is at the transcrip-
tional level (Fig. 6E).
SAT1 knockdown reduces H3 acetylation at the BRCA1
promoter
Increased H3 acetylation at the BRCA1 promoter has been
reported to regulate BRCA1 transcription (24). Recent studies
have demonstrated a link between elevated levels of spermi-
dine and histone deacetylation in aging yeast (25). We hypoth-
esized that alterations in SAT1 levels may affect BRCA1 tran-
scription through regulation of chromatin access via histone
acetylation. We ﬁrst assessed global histone H3 acetylation on
Figure 4. Polyamine levels are
unchanged by stable knockdown
of SAT1. A, acetyl-spermine (Ac-
Spm), spermine (Spm), acetyl-
spermidine (Ac-Spd), and
spermidine (Spd) were measured
by MS in D54MG shGFP and
shSAT1 cells. B, qRT-PCR of ODC
and SAT1 mRNA in stable SAT1
knockdown cells; error bars, SDs.
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cell lysates and found in both U87MG and D54MG cell lines
that SAT1 knockdown resulted in decreased N-terminal H3
acetylation (Fig. 6G).Wenext assessed the levels of acetyl-H3 at
the BRCA1 promoter via ChIP and found similarly that the
knockdown populations exhibited decreased levels of acety-
lated H3 localized to the BRCA1 promoter. In contrast, the
b-actin promoter displayed mild increases in H3 acetylation
(Fig. 6F). To determine whether reversing the reduction in
histone acetylation would restore BRCA1 levels, we treated
D54MG shGFP and shSAT1 cells with the HDAC (histone
deacetylase) inhibitor TSA and found increased H3 acetylation
and induction of BRCA1 mRNA (Fig. 6H). Thus, the data
suggest that SAT1 promotes acetylation of histone H3 on the
BRCA1 promoter, thereby inducing BRCA1 expression and
facilitating HR repair.
SAT1 and BRCA1 expression correlate in glioma
To validate the concept that SAT1 mediates poor outcome
and potentially response to therapy through BRCA1 expres-
sion, we sought to determine whether SAT1 and BRCA1
expression correlate in the Rembrandt data presented
in Fig. 1D. Indeed, SAT1 and BRCA1 expression correlate with
statistical signiﬁcance (P ¼ 0.0118; Fig. 7A), and BRCA1
expression revealed an outcome beneﬁt for patients with lower
expression as opposed to higher expression (P ¼ 0.0001; Fig.
7B). Together, the clinical data support the importance of both
SAT1 and BRCA1 in predicting patient outcomes, and suggest
BRCA1 is at least partially responsible for the radioresistance of
SAT1-overexpressing tumors.
Discussion
In the present study, we have identiﬁed a novel mechanism
of radioprotection in glioblastoma linked to the frequent
overexpression of the polyamine catabolic enzyme SAT1. SAT1
is overexpressed almost uniformly in GBM tumor samples
compared with normal brain, as assessed bioinformatically in
the Oncomine and TCGA databases. Depletion of SAT1 radio-
sensitized multiple adherent cell lines and neurosphere lines,
and tumors in mice. Mechanistically, we found that SAT1
promotes HR by controlling BRCA1 expression and BRCA1
foci following damage to DNA. We elucidated a novel function
for SAT1 as a mediator of histone H3 acetylation controlling
BRCA1 gene expression. Together, our ﬁndings highlight a
previously unappreciated role for the polyamine metabolic
pathway in regulating radiation responses in tumors, and
identify a potential target for radiosensitizers to improve
therapeutic efﬁcacy.
Polyamines, including putrescine, spermine, and spermi-
dine, are ubiquitous cellular constituents present inmillimolar
quantities. As positively charged small molecules, polyamines
bind negatively charged macromolecules throughout cells,
including nucleic acids and proteins, and regulate many pro-
cesses (26). Polyamines promote protection to IR by inducing
DNA compaction, producing a less susceptible target to direct
radiation damage (8, 9, 27). SAT1, however, is the rate-limiting
enzyme in polyamine catabolism, driving acetylation, and
subsequent degradation or excretion of polyamines. Indeed,
acetylation has been shown to result in removal of polyamines
from chromatin, leading to chromatin relaxation and opening
Figure 5. SAT1 protects cells from IR by promoting HR. A, cell-cycle proﬁles of D54MG shGFP and shSAT1 cells. B, SAT1 qRT-PCR in asynchronous and
ﬂow-sorted cells normalized to b-actin. C, clonogenic survival assays of ﬂow-sorted D54MG shGFP or shSAT1 cells; , P values all 0.039. D, DR-GFP
HR reporter assay in shSAT1 or shScramMCF7 cells. Mean efﬁciencies were 0.187% GFP-positive cells for control, and 0.089% for shSAT1. E, clonogenic
survival of D54MG shGFP and shSAT1 cells with CPT; error bars, SDs.
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(28). Thus, existing data do not provide a mechanistic expla-
nation for the role of SAT1 in radioprotection.
A recent proteomics study drew a connection between
polyamine acetylation in radioresponse, ﬁnding acetyl-sper-
midine as a blood-borne biomarker in mice exposed to whole-
body radiation (29). Aged mice showed a diminished ability to
induce acetyl-spermidine following exposure, suggesting that
aging-related decreases in DNA repair correlate with reduced
polyamine catabolism. Although the mechanism behind the
observations was not fully uncovered, the data intriguingly
suggest that acetylated polyamines may provide a noninvasive
marker of radiation responses.
To assess the effect of SAT1 expression on homeostatic
polyamine levels in our system, we quantiﬁed cellular poly-
amines and found negligible differences. Although not surpris-
ing that cells acclimate to decreased SAT1 by reducing
Figure 6. SAT1 depletion decreases
BRCA1 levels. A, comet assay of
shGFP and shSAT1 D54MG cells
after 10 Gy IR at indicated times. B,
immunoﬂuorescence of BRCA1
foci. C, quantiﬁcation of # foci/cell.
D, Western blotting of HR proteins
and acetylated or total histone H3
in shSAT1 cells versus controls. E,
qRT-PCR of BRCA1 in shSAT1
cells versus controls. F, ChIP of
acetylated H3 at the BRCA1 and
b-actin promoters in shSAT1 GBM
cells versus controls. G, Western
blot analysis for acetylated H3 in
D54MG shGFP and shSAT1 cells
with TSA. H, qRT-PCRof BRCA1 in
D54MG shGFP and shSAT1 cells
with TSA; error bars, SDs.
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expression of ODC1 via described feedback loops (21), the data
suggest that regulating global polyamine levels is not the
mechanism of radioprotection by SAT1. Recent data have
demonstrated, however, that controlling localized polyamine
content is also an important function of SAT1. SAT1 has been
found to modulate cell migration through an interaction with
a9b1 integrin, localizing polyamine catabolism to membrane-
bound potassium channels. Because spermine and spermidine
are potassium channel blockers, the association of SAT1 with
a9b1 in focal adhesions at the leading edges of migrating cells
allows ion channel regulation (30). Thus, our data do not rule
out that controlling localized polyamines at damage sites may
be a mode by which SAT1 can affect radiation response.
Alternatively, the ﬁndings point to a novel mechanism of
SAT1 in regulating histone acetylation. Excess polyamines have
been recently shown to prolong lifespan via elevated autop-
hagy due to alterations in histone acetylation and subsequent
induction of autophagy genes (25). Furthermore, depletion of
polyamines led to hyperacetylation of histoneH3, generation of
reactive oxygen species (ROS), and ultimately necrosis. Con-
versely, spermidine treatment caused deacetylation of histone
H3 through inhibition of histone acetyltransferases. Concep-
tually, the ﬁndings agree with ours, that by decreasing poly-
amines, SAT1 would promote acetylation of H3 and subse-
quently alter gene expression. In our studies, however, the
importance of polyamines was unclear. As an acetyl-transfer-
ase, it is unknownwhether SAT1 can also target proteins, as no
speciﬁc targets have been identiﬁed beyond an autoacetylation
activity (7). In yeast, the hpa1 and hpa2 genes, though struc-
turally unrelated to SAT1, have been found to be capable of
acetylating both polyamines and histones (31). In vitro, wewere
unable to detect a direct acetylation activity of puriﬁed SAT1
on puriﬁed histone H3, however, leaving open the question of a
direct or indirect effect of SAT1 on histones. Alternatively, the
observation that the HDAC inhibitor reversed the acetylation
status of H3 and rescued BRCA1 levels may suggest that SAT1
can function as an HDAC inhibitor. Future studies will be
necessary to bear out this possibility.
Polyamine analogues have long been a focus of development
of anticancer agents (32, 33). The mechanism of cell death by
analogues is due to potent induction of SAT1 (>1,000-fold),
leading to polyamine depletion and excess production of ROS
(21). Ectopic overexpression of SAT1 is also toxic due to
inhibition of general protein translation (34). To avoid com-
plications of nonphysiologic alterations in SAT1 levels, we
focused on shRNAs that reduced SAT1 levels to the range
observed in normal brain (3- to 5-fold reductions in the GBM
lines). In this context, our data suggest that decreasing SAT1
may have therapeutic beneﬁt. Furthermore, sensitizing brain
tumors with an SAT1 inhibitor may have relevance in combi-
nation with Parp inhibitors, which take advantage of altera-
tions in the BRCA1 pathway and have recently been shown to
sensitize brain tumor-initiating cells to radiation (35).
In summary, we have deﬁned a novel function for the
polyamine catabolic enzyme SAT1 in mediating HR repair in
brain tumors through the epigenetic regulation of BRCA1. Our
ﬁndings describe a new mechanism for SAT1 to regulate
chromatin, and suggest that inhibition of SAT1 may sensitize
brain tumors to radiation and increase therapeutic responses.
Together, the ﬁndings contribute to our understanding of
radioresistance in GBM, and may have yet even broader
implications due to the overexpression of polyaminemetabolic
enzymes in a variety of other tumors (36).
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